Company intelligence / Profile preview

MELISA Institute

Ownership: Private
Development stage: Preclinical

Overview

MELISA Institute’s lead investigational therapy, Previfenon®️—a stabilized complex of EGCG and zinc—is being developed as a prenatal therapeutic agent to improve neurodevelopmental outcomes in trisomy 21 by inhibiting DYRK1A. It also has immunomodulatory and antiviral properties under investigation for epidemic virus prevention. The institute runs the EARLY-PREG cohort study to identify ultra-early pregnancy biomarkers through proteomic and transcriptomic analysis.

Therapeutic areas: NeurologyInfectious Diseases
Modalities: Small moleculeMetal complex
Industry: Academic Hospital/University/Research

Drug pipeline

1 asset

Previfenon

Pre-clinical

Indications: Trisomy 21, COVID-19

Beyond the preview

Go deeper on MELISA Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MELISA Institute.

Explore the full profile